Antisense Therapeutics Limited announced the commencement of Dr. James Garner as Chief Executive Officer and Managing Director, effective 7 August 2023. Dr. Garner's appointment was previously announced to ASX on 8 May 2023, and he has served as a non- executive Director of the company since that date. Dr. Garner is a physician and MBA graduate, and brings to Antisense more than twenty years of international experience in drug development, gleaned in companies such as Biogen, Sanofi, Takeda, and, most recently, as Chief Executive Officer and Managing Director of Kazia Therapeutics Limited.

Prior to joining the pharmaceutical industry, Dr. Garner worked as a management consultant with Bain & Company. As part of the leadership transition, Dr Charmaine Gittleson will step back from executive responsibilities and will resume her role as Non-Executive Chair of the company.